Cargando…

Precision Nutrition and Cardiovascular Disease Risk Reduction: the Promise of High-Density Lipoproteins

PURPOSE OF REVIEW: Emerging evidence supports the promise of precision nutritional approaches for cardiovascular disease (CVD) prevention. Here, we discuss current findings from precision nutrition trials and studies reporting substantial inter-individual variability in responses to diets and dietar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Brian V., Agus, Joanne K., Tang, Xinyu, Zheng, Jack Jingyuan, Romo, Eduardo Z., Lei, Susan, Zivkovic, Angela M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564829/ https://www.ncbi.nlm.nih.gov/pubmed/37702886 http://dx.doi.org/10.1007/s11883-023-01148-5

Ejemplares similares

High-Density Lipoprotein Changes in Alzheimer’s Disease Are APOE Genotype-Specific
por: Hong, Brian V., et al.
Publicado: (2022)

Glycosylation of HDL-Associated Proteins and Its Implications in Cardiovascular Disease Diagnosis, Metabolism and Function
por: Romo, Eduardo Z., et al.
Publicado: (2022)

Quantitative glycoproteomics of high-density lipoproteins
por: Tang, Xinyu, et al.
Publicado: (2022)

A single 36-h water-only fast vastly remodels the plasma lipidome
por: Hong, Brian V., et al.
Publicado: (2023)

Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins
por: Lawler, Patrick R., et al.
Publicado: (2017)

High-Density Lipoproteins in Non-Cardiovascular Diseases
por: Zanotti, Ilaria
Publicado: (2022)

High density lipoproteins-based therapies for cardiovascular disease
por: Gao, Xuan, et al.
Publicado: (2010)

Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research
por: Kornmueller, Karin, et al.
Publicado: (2019)

Lipoprotein(a): A Promising Marker for Residual Cardiovascular Risk Assessment
por: Cai, Anping, et al.
Publicado: (2013)

Plasma Lecithin-Cholesterol Acyltransferase Activity in Pregnant Women Enrolled in the iLiNS-DYAD Trial in Ghana
por: Hong, Brian, et al.
Publicado: (2022)

Age and Cardiovascular Risk Attributable to Apolipoprotein B, Low‐Density Lipoprotein Cholesterol or Non‐High‐Density Lipoprotein Cholesterol
por: Sniderman, Allan D., et al.
Publicado: (2016)

Changes in high-density lipoprotein cholesterol with risk of Cardiovascular Disease among initially high-density lipoprotein-high participants
por: Kim, Hye Jun, et al.
Publicado: (2023)

Low‐Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events
por: Willeit, Peter, et al.
Publicado: (2020)

Multi-Omic Analyses Reveal Bifidogenic Effect and Metabolomic Shifts in Healthy Human Cohort Supplemented With a Prebiotic Dietary Fiber Blend
por: Kang, Jea Woo, et al.
Publicado: (2022)

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad and the Future
por: Julve, Josep, et al.
Publicado: (2021)

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future
por: Julve, Josep, et al.
Publicado: (2021)

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
por: Henry, Courtney A, et al.
Publicado: (2016)

Glycomic Analysis of High Density Lipoprotein Shows a Highly Sialylated Particle
por: Huang, Jincui, et al.
Publicado: (2014)

Anti-high-density lipoprotein antibodies and lipoprotein characteristics in systemic lupus erythematosus-related cardiovascular disease
por: Su, J, et al.
Publicado: (2005)

Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis
por: Ennezat, Pierre Vladimir, et al.
Publicado: (2022)

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk
por: Hafiane, Anouar, et al.
Publicado: (2015)

High Density Lipoprotein Cholesterol Increasing Therapy: The Unmet Cardiovascular Need
por: Cimmino, Giovanni, et al.
Publicado: (2014)

Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease
por: Estrada-Luna, Diego, et al.
Publicado: (2018)

PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers
por: González, Fátima E. Murillo, et al.
Publicado: (2019)

High-Density Lipoproteins and Cardiovascular Disease: The Good, the Bad, and the Future II
por: Julve, Josep, et al.
Publicado: (2022)

Current Status of Low-Density Lipoprotein Cholesterol and Cardiovascular Diseases in Japan
por: Sun, Wanlu, et al.
Publicado: (2023)

Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol
por: Lawler, Patrick R., et al.
Publicado: (2017)

Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study
por: Hajian-Tilaki, Karimollah, et al.
Publicado: (2020)

Commentary on High-density Lipoprotein Versus Low-density Lipoprotein Therapy and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes by Nikolaos Papageorgiou et al.
por: Owens, D.A., et al.
Publicado: (2018)

Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk
por: Glavinovic, Tamara, et al.
Publicado: (2022)

Prolonged Fasting Alters the Size, Function, and Glycoproteomic Profile of HDL Particles
por: Agus, Joanne, et al.
Publicado: (2022)

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
por: Chapman, M. John, et al.
Publicado: (2011)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
por: Ito, Fumiaki, et al.
Publicado: (2020)

The association of financial incentives for low density lipoprotein cholesterol reduction with patient activation and motivation
por: Liu, Tianyu, et al.
Publicado: (2019)

High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
por: Kapur, Navin K, et al.
Publicado: (2008)

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit
por: McTaggart, Fergus, et al.
Publicado: (2008)

Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease
por: Besler, Christian, et al.
Publicado: (2012)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
por: Kosmas, Constantine E, et al.
Publicado: (2018)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Low‐Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific
por: Cupido, Arjen J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qnr4kq3sun3beu8h4hj3p5itcr